Parkinson's disease
Conditions
Interventions
None listed
Sponsors
Tridem Bioscience GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Outcome results
None listed
A Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 1b Study to Assess the Safety, Immunogenicity and Pharmacodynamics of TRB-001 in Early Idiopathic Parkinson’s Disease Patients
For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms
Source: EU CTIS · Data processed: Jul 11, 2026